Zajištění operačních výkonů u pacientů s von Willebrandovou chorobou preparátem Wilate® – první klinické zkušenosti jednoho centra v ČR
Authors:
R. Hrdličková 1; Š. Blahutová 1; O. Šimetka 2
; J. Zuchnická 3; Z. Čermáková 2
Authors‘ workplace:
Krevní centrum Fakultní nemocnice Ostrava
1; Lékařská fakulta Ostravské univerzity
2; Ústav klinické hematologie Fakultní nemocnice Ostrava
3
Published in:
Transfuze Hematol. dnes,18, 2012, No. 4, p. 165-168.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
The authors introduce first experiences of their centre with perioperative management of three patients with von Willebrand disease (type 1, type 2 and acquired von Willebrand syndrom) by replacement therapy with Wilate®, which is a new generation of plasma concentrate vWF/FVIII with high-purity and double virus inactivation. In all our cases, Wilate® was effective for maintaining haemostasis and prevention of bleeding from soft tissues and mucous.
Key words:
von Willebrand disease, perioperative bleeding, Wilate®
Sources
1. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 : 171–232.
2. Smejkal P, Matýšková M, Penka M. Von Willebrandova choroba. Vnitř Lék 2008; 257–264.
3. Stadler M, Gruber G, Kannicht C, et al. Characterization of novel high purity, double virus inactivated von Willebrand factor and factor VIII concentrate (Wilate). Biologicals 2006; 34 : 281–288.
4. Kessler CM, Friedman K, Schwartz AB, et al. The pharmacokinetic diversity of two von Willebrand factor (VWF) / factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Tromb Haemost 2011; 106 (2): 279–288.
5. Windyga J, Prondzinski M, et al. Efficacy and safety of new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Tromb Haemost 2011; 105 : 1072–1079.
6. Mannucci PM, Federici AB, James AH, Kessler CM. Von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia 2009; 15 : 1154–1158.
7. Mannucci PM. Treatment of von Willebrand´s disease. N Engl J Med 2004; 351 : 683–694.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2012 Issue 4
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
- Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy
Most read in this issue
- První zkušenosti jednoho centra s použitím přípravku Octaplas® v léčbě pacientky s vrozenou formou trombotické trombocytopenické purpury
- Zajištění operačních výkonů u pacientů s von Willebrandovou chorobou preparátem Wilate® – první klinické zkušenosti jednoho centra v ČR
- Supportive therapy with megestrol acetate in myeloproliferative neoplasms
- The use of natural colloids in fluid resuscitation of severely burned patients